Key facts
- It has raised $460K across 1 recorded rounds; the latest was Seed Round ($458K) in Jan 2023.
- Notable investors include Ben Franklin Technology Partners of Northeastern Pennsylvania, Brain Chile, Life Sciences Greenhouse Investments.
- Ilico Genetics has filed 1 Form D with the SEC, most recently Oct 2023 ($458K sold to 10 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for Ilico Genetics
Funding rounds
1 roundsAbout Ilico Genetics
Developer of molecular diagnostic technology designed for the early detection of gastric cancer. The company uses a methylated DNA-based liquid biopsy test that relies on a blood sample to identify tumors or precancerous lesions before symptoms emerge, supports dynamic monitoring of gastric intestinal metaplasia, facilitates timely patient prioritization, enabling healthcare providers to improve diagnostic accuracy, streamline treatment decisions, and enhance long-term outcomes through non-invasive genomic analysis.
- Sector
- Healthcare
- HQ
- Bethlehem, PA, United States
- Founded
- 2020
- Employees
- 6
- Website
- ilicogenetics.com/
- Ownership
- Privately Held (backing)
Ilico Genetics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Ilico Genetics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Ilico Genetics in its N-PORT filings yet. We sweep new filings monthly.